focus -WSS

focus

author：Wikipedia 2025-09-29 23:28:19 - browse：15

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： H5N1 communication has been strictly for the birds

knowledge

WSS

Dairy farmers resist CDC push for PPE against bird flu virus

Why the quest to eradicate polio has stumbled

FDA weighs limits of animal data in assessing artificial wombs

First recipient of genetically engineered pig kidney has died

Why the quest to eradicate polio has stumbled

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: What to know about H5N1 bird flu

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

H5N1 bird flu: what we're starting to learn about infection in cows

State Dept. review finds Biden bears some blame for Afghanistan failures

Study: Adult vaccinations pay for themselves in societal benefits

Psychedelics group wrestles with new pharma identity

PBMs drew scrutiny in House hearing — and so did pharma

Hollywood unions extend contract negotiations for actors

H5N1 communication has been strictly for the birds

explore

Brain worms: The science behind RFK Jr.'s parasitic infection

Medicare says breakthrough device reimbursement rule to come by summer

Researchers on aging grapple with how to calculate biological age

PBMs drew scrutiny in House hearing — and so did pharma

Grad students accuse University of California of wage theft

'A game

entertainment

focus

knowledge

explore